CP101 Chronic Hepatitis B Pipeline Report 2023: Emerging Drug Insights and Market Forecasts, 2019-2032

Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) — The “CP101 Emerging Drugs Insights and Market Forecasts – 2032” report has been added to ResearchAndMarkets.com Dedication.

The “CP101 Emerging Drug Insights and Market Forecasts – 2032” report provides comprehensive insights into CP101 for the treatment of Clostridium difficile infection (CDI) in seven key markets.

Developed by Finch Therapeutics, CP101 is an investigational oral microbiome medicine for the treatment of diseases associated with microbiome dysfunction. CP101 delivers an intact microbial community via oral enteric-coated capsules. The drug is in late-stage clinical development to prevent rCDI. The company plans to use CP101 for other diseases associated with microbiome disruption, first evaluating CP101 as a treatment for chronic hepatitis B.

Recently, the U.S. FDA canceled the clinical hold on the investigational new drug (IND) application for Finch CP101. The company has continued patient dosing in the PRISM4 (Phase III) trial of CP101 to prevent rCDI and expects topline data from PRISM4 to be available in the first half of 2024.

This report provides details of CP101 for C. difficile infection in 7MM (i.e., United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) during the study period 2019-2032 and a detailed description of CP101 for C. difficile infection .

The report provides insights into mechanism of action, dosage and administration, as well as research and development (including regulatory milestones) and other development activities.

Furthermore, it also includes future market assessment including CP101 market forecast analysis for Clostridium difficile infection in 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and a profile of other emerging therapies regarding Clostridium difficile infection.

CP101 Analysis Perspective
Yo

The story continues

n In-depth CP101 market assessment

This report provides a detailed market assessment of CP101 for the treatment of Clostridium difficile infection in seven major markets: the United States, EU4 (Germany, France, Italy and Spain), the United Kingdom and Japan. This section of the report provides forecast sales data from 2025 to 2032.

CP101 Clinical Assessment

This report provides information on clinical trials of CP101 for the treatment of Clostridium difficile infection, including trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• The Clostridium difficile infection market landscape is set to change in the coming years due to extensive research and increasing healthcare spending across the world; this will expand the market size and enable pharmaceutical manufacturers to penetrate the market more.

• The therapies being developed by these companies are focused on new approaches to treat/modify disease conditions, assess challenges, and identify opportunities that may impact CP101 dominance.

• Other emerging products for the treatment of C. difficile infections are expected to bring intense market competition to CP101, and the launch of late-stage emerging therapies in the near future will have a significant impact on the market.

• A detailed description of regulatory milestones and development activities provides the current development scenario for CP101 in C. difficile infection.

• An in-depth analysis of CP101 forecast sales data from 2025 to 2032 will support customers in the decision-making process for their treatment combinations by determining the overall profile of CP101 in C. difficile infections.

Key topics covered:

1. Introduction to the report

2. Overview of CP101 in Clostridium difficile infection
2.1. Product details
2.2. Clinical development
2.2.1. Clinical research
2.2.2. Clinical trial information
2.2.3. Safety and effectiveness
23. Other development activities
2.4. Product introduction

3. Competitive landscape (marketed therapies)

4. Competitive landscape (late-stage emerging therapies)

5. CP101 market assessment
5.1. Market prospects of CP101 in Clostridium difficile infection
5.2. 7MM analysis
5.2.1. CP101 market size in 7MM Clostridium difficile infection
5.3. Country/Region Market Analysis
5.3.1. Market size of CP101 for Clostridium difficile infection in the United States
5.3.2. Market size of CP101 for Clostridium difficile infection in Germany
5.3.3. Market size of CP101 for Clostridium difficile infection in France
5.3.4. Market size of CP101 for Clostridium difficile infection in Italy
5.3.5.Market size of CP101 for Clostridium difficile infection in Spain
5.3.6.UK market size of CP101 for Clostridium difficile infection
5.3.7. Market size of CP101 for Clostridium difficile infection in Japan

6.SWOT analysis

7. Analysts’ views

8. Appendix

For more information about this report, please visit https://www.researchandmarkets.com/r/b0h4bb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900